GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » EPS without NRI
Switch to:

Incyte EPS without NRI

: $4.25 (TTM As of Jun. 2022)
View and export this data going back to 1993. Start your Free Trial

Incyte's earnings per share without non-recurring items for the three months ended in Jun. 2022 was $0.72. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $4.25.

During the past 12 months, Incyte's average earnings per share (NRI) Growth Rate was 179.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 103.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Incyte's EPS without NRI or its related term are showing as below:

INCY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.1   Med: 11.8   Max: 157.1
Current: 103.1

During the past 13 years, Incyte's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 157.10% per year. The lowest was -74.10% per year. And the median was 11.80% per year.

INCY's 3-Year EPS without NRI Growth Rate is ranked better than
98.44% of 1151 companies
in the Biotechnology industry
Industry Median: 7.50 vs INCY: 103.10

Incyte's EPS (Diluted) for the three months ended in Jun. 2022 was $0.72. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $4.25.

Incyte's EPS (Basic) for the three months ended in Jun. 2022 was $0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $4.27.


Incyte EPS without NRI Historical Data

The historical data trend for Incyte's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.53 0.51 2.05 -1.36 4.27

Incyte Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.82 2.54 0.17 0.72

Competitive Comparison

For the Biotechnology subindustry, Incyte's EPS without NRI, along with its competitors' market caps and EPS without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte EPS without NRI Distribution

For the Biotechnology industry and Healthcare sector, Incyte's EPS without NRI distribution charts can be found below:

* The bar in red indicates where Incyte's EPS without NRI falls into.



Incyte EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte  (NAS:INCY) EPS without NRI Explanation

A Non Operating Income refers to an entry that appears on a company's financial statements that is unlikely to happen again. It represents a one-time expense involving an unpredictable event and is not part of a firm's normal, day-to-day operations.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Incyte EPS without NRI Related Terms

Thank you for viewing the detailed overview of Incyte's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Incyte logo
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Tray Thomas officer: Principal Accounting Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W director 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A director 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund director
Morrissey Michael James officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E officer: EVP & General Counsel C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A director C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J director C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques director 925 PAGE MILL ROAD PALO ALTO CA 94304

Incyte Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)